Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCCNASDAQ:SIGANASDAQ:TECXNASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$1.38+0.7%$1.52$1.09▼$7.66$97.99M3.11.39 million shs453,269 shsSIGASIGA Technologies$5.91+1.2%$5.82$4.95▼$12.83$422.22M0.92732,354 shs479,585 shsTECXTectonic Therapeutic$21.65-2.5%$19.36$13.70▼$61.07$404.27M3.44175,282 shs109,014 shsTRMLTourmaline Bio$15.32+0.3%$15.43$11.56▼$29.79$393.49M2.11275,981 shs142,435 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics+0.74%-0.72%-12.18%-54.49%-76.38%SIGASIGA Technologies-4.73%-1.35%-4.73%-1.18%-21.93%TECXTectonic Therapeutic-1.68%+7.30%+13.90%-24.85%+2,219,999,900.00%TRMLTourmaline Bio+1.06%-1.61%-11.84%+25.06%+12.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCCCC4 Therapeutics2.6189 of 5 stars3.33.00.00.03.71.70.6SIGASIGA Technologies1.3792 of 5 stars0.01.00.00.02.20.83.1TECXTectonic Therapeutic3.4805 of 5 stars3.63.00.00.02.85.00.6TRMLTourmaline Bio1.8531 of 5 stars3.51.00.00.02.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.50Moderate Buy$12.00769.57% UpsideSIGASIGA Technologies 0.00N/AN/AN/ATECXTectonic Therapeutic 3.14Buy$79.20265.82% UpsideTRMLTourmaline Bio 3.00Buy$49.33222.02% UpsideCurrent Analyst Ratings BreakdownLatest CCCC, TECX, SIGA, and TRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$51.00 ➝ $85.005/5/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.005/5/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/23/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.004/21/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$51.003/21/2025TECXTectonic TherapeuticWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$112.00 ➝ $101.003/14/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.003/14/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $50.003/6/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.002/24/2025TRMLTourmaline BioLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$58.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$39.78M2.46N/AN/A$4.07 per share0.34SIGASIGA Technologies$120.33M3.51$0.93 per share6.34$2.77 per share2.13TECXTectonic TherapeuticN/AN/AN/AN/A$2.13 per shareN/ATRMLTourmaline BioN/AN/AN/AN/A$10.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$132.49M-$1.47N/AN/AN/A-313.35%-42.45%-27.55%8/7/2025 (Estimated)SIGASIGA Technologies$68.07M$0.674.934.73N/A49.33%49.06%38.72%8/7/2025 (Estimated)TECXTectonic Therapeutic$12.16M-$7.31N/AN/AN/AN/A-35.53%-31.97%N/ATRMLTourmaline Bio-$42.12M-$3.21N/AN/AN/AN/A-20.97%-20.56%N/ALatest CCCC, TECX, SIGA, and TRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SIGASIGA TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 million5/8/2025Q1 2025TECXTectonic Therapeutic-$1.10-$0.93+$0.17-$0.93N/AN/A5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million5/2/2025Q1 2025TRMLTourmaline Bio-$0.91-$0.89+$0.02-$0.89N/AN/A3/20/2025Q4 2024TECXTectonic Therapeutic-$1.39-$0.84+$0.55-$0.84N/AN/A3/13/2025Q4 2024TRMLTourmaline Bio-$0.91-$0.86+$0.05-$0.86N/A$0.04 million3/11/2025Q4 2024SIGASIGA TechnologiesN/A$0.63N/A$0.63N/A$81.40 million2/27/2025Q4 2024CCCCC4 Therapeutics-$0.44-$0.49-$0.05-$0.49$4.43 million$5.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ALatest CCCC, TECX, SIGA, and TRML DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/8/2025SIGASIGA Technologiesspecial$0.604/29/20254/29/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A6.316.31SIGASIGA TechnologiesN/A8.105.32TECXTectonic TherapeuticN/A9.399.39TRMLTourmaline BioN/A40.3340.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%SIGASIGA Technologies55.40%TECXTectonic Therapeutic62.63%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%SIGASIGA Technologies1.54%TECXTectonic Therapeutic38.00%TRMLTourmaline Bio11.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15071.01 million64.55 millionOptionableSIGASIGA Technologies4071.44 million70.31 millionOptionableTECXTectonic Therapeutic12018.67 million13.40 millionN/ATRMLTourmaline Bio4425.69 million22.82 millionOptionableCCCC, TECX, SIGA, and TRML HeadlinesRecent News About These CompaniesBMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)May 23 at 10:04 AM | msn.comWexford Capital LP Purchases New Position in Tourmaline Bio, Inc. (NASDAQ:TRML)May 22 at 5:34 AM | marketbeat.comTourmaline shares waver as investors mull mid-stage pacibekitug dataMay 21 at 6:19 PM | thepharmaletter.comTourmaline Bio, Inc. (NASDAQ:TRML) Stake Increased by Velan Capital Investment Management LPMay 21 at 8:23 AM | marketbeat.comTourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease winMay 21 at 12:18 AM | fiercebiotech.comTourmaline Bio posts mid-stage data for anti-inflammatory agentMay 21 at 12:18 AM | msn.comTourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 InhibitionMay 20 at 5:08 PM | seekingalpha.comTourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025May 19, 2025 | globenewswire.comContrasting Exelixis (NASDAQ:EXEL) & Tourmaline Bio (NASDAQ:TRML)May 16, 2025 | americanbankingnews.comAnalysts Set Expectations for Tourmaline Bio FY2025 EarningsMay 10, 2025 | marketbeat.comLeerink Partnrs Comments on Tourmaline Bio FY2025 EarningsMay 10, 2025 | marketbeat.comBrokers Set Expectations for Tourmaline Bio FY2025 EarningsMay 9, 2025 | marketbeat.comQ2 EPS Estimates for Tourmaline Bio Decreased by AnalystMay 9, 2025 | marketbeat.comLeerink Partnrs Weighs in on Tourmaline Bio Q2 EarningsMay 9, 2025 | marketbeat.comAlyeska Investment Group L.P. Lowers Position in Tourmaline Bio, Inc. (NASDAQ:TRML)May 9, 2025 | marketbeat.comHC Wainwright Weighs in on Tourmaline Bio Q2 EarningsMay 8, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from HC WainwrightMay 7, 2025 | marketbeat.comTourmaline Bio's (TRML) "Buy" Rating Reiterated at Chardan CapitalMay 7, 2025 | marketbeat.comTourmaline Bio (TRML) Expected to Announce Earnings on MondayMay 7, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLCMay 7, 2025 | marketbeat.comTourmaline Bio Reports Q1 2025 Financial ResultsMay 7, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC, TECX, SIGA, and TRML Company DescriptionsC4 Therapeutics NASDAQ:CCCC$1.38 +0.01 (+0.73%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.00 (+0.29%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.SIGA Technologies NASDAQ:SIGA$5.91 +0.07 (+1.20%) Closing price 04:00 PM EasternExtended Trading$5.99 +0.08 (+1.42%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Tectonic Therapeutic NASDAQ:TECX$21.65 -0.55 (-2.48%) Closing price 04:00 PM EasternExtended Trading$21.72 +0.07 (+0.30%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Tourmaline Bio NASDAQ:TRML$15.32 +0.05 (+0.33%) Closing price 04:00 PM EasternExtended Trading$15.68 +0.37 (+2.38%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
